Literature DB >> 3178533

Short course of albendazole therapy for neurocysticercosis.

J Sotelo1, P Penagos, F Escobedo, O H Del Brutto.   

Abstract

Albendazole is now used for therapy of neurocysticercosis; however, duration of treatment has usually been empirically determined. In this study we shortened the length of therapy from one month in previous reports, to one week. Twelve patients with parenchymal brain cysticercosis were treated with albendazole for eight days at daily doses of 15 mg/kg of body weight. After three months of treatment the number of cysts on computed tomography had decreased from 185 to six; a 97% reduction in the number of lesions. Total remission of all cysts was seen in nine patients. Two cases had been unsuccessfully treated before with praziquantel, in both instances albendazole therapy was effective with 100% improvement. Our results indicated that a short course of albendazole is highly effective for treatment of neurocysticercosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3178533     DOI: 10.1001/archneur.1988.00520340084017

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  13 in total

1.  High-dose praziquantel with cimetidine for refractory neurocysticercosis: a case report with clinical and MRI follow-up.

Authors:  T Yee; J A Barakos; R T Knight
Journal:  West J Med       Date:  1999-02

2.  Childhood neurocysticercosis in south India.

Authors:  L C Thakur; K S Anand
Journal:  Indian J Pediatr       Date:  1991 Nov-Dec       Impact factor: 1.967

3.  Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis.

Authors:  J Sotelo; O H del Brutto; P Penagos; F Escobedo; B Torres; J Rodriguez-Carbajal; F Rubio-Donnadieu
Journal:  J Neurol       Date:  1990-04       Impact factor: 4.849

4.  A Personal Account Regarding the Origin and Evolution of Controversies in the Management of Neurocysticercosis.

Authors:  Oscar H Del Brutto
Journal:  Am J Trop Med Hyg       Date:  2019-04       Impact factor: 2.345

Review 5.  Cysticercosis and cerebrovascular disease: a review.

Authors:  O H Del Brutto
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-04       Impact factor: 10.154

6.  Albendazole in neurocysticercosis.

Authors:  D Kapil; P Vohra
Journal:  Indian J Pediatr       Date:  1993 Jan-Feb       Impact factor: 1.967

7.  Concentrations of albendazole in serum, cerebrospinal fluid and hydatidous brain cyst.

Authors:  D Moskopp; E Lotterer
Journal:  Neurosurg Rev       Date:  1993       Impact factor: 3.042

8.  Oral albendazole in the management of extraocular cysticercosis.

Authors:  R Sihota; S G Honavar
Journal:  Br J Ophthalmol       Date:  1994-08       Impact factor: 4.638

Review 9.  Neurocysticercosis: a review on status in India, management, and current therapeutic interventions.

Authors:  Rumana Ahmad; Tahmeena Khan; Bilal Ahmad; Aparna Misra; Anil K Balapure
Journal:  Parasitol Res       Date:  2016-10-24       Impact factor: 2.289

10.  Antiparasitic drugs in neurocysticercosis: albendazole or praziquantel?

Authors:  Hector H Garcia
Journal:  Expert Rev Anti Infect Ther       Date:  2008-06       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.